We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Metallopolymers Protect Penicillin-Like Antibiotics from Bacterial Beta-Lactamase

By LabMedica International staff writers
Posted on 12 May 2014
Novel drug combinations that unite classical penicillin-like antibiotics with metallopolymers effectively kill bacteria, including "superbugs" such as MRSA (methicillin-resistant Staphylococcus aureus) that had developed beta-lactamase enzyme-based resistance to the antibiotics.

Metallopolymers are a class of polymers with metal atoms either in the backbone or at the side chain. More...
These polymers exhibit many unprecedented properties and functions that conventional organic polymers usually lack. Among metallopolymers, metallocene-containing polymers have attracted significant attention due to their unique electrochemical, catalytic, and optical properties. Metallocene-containing polymers are widely used for redox active systems as recognition of ions and sugars and modification of electrodes.

MRSA, a complex of multi-drug-resistant Gram-positive bacterial strains, has proven especially problematic in both hospital and community settings by deactivating conventional beta-lactam antibiotics, including penicillins, cephalosporins, and carbapenems, through various mechanisms, resulting in increased mortality rates and hospitalization costs.

To correct this problem, investigators at the University of South Carolina (Columbia, USA) developed an improved class of beta-lactam antibiotics by conjugating classical penicillin-like antibiotics to cobaltocenium metallopolymers.

They reported in the March 17, 2014, online edition of the Journal of the American Chemical Society that these combinations exhibited a synergistic effect against MRSA by efficiently inhibiting activity of beta-lactamase and effectively lysing bacterial cells. Various conventional beta-lactam antibiotics, including penicillin-G, amoxicillin, ampicillin, and cefazolin, were protected from beta-lactamase hydrolysis via the formation of unique ion-pairs between their carboxylate anions and cationic cobaltocenium moieties.

"Instead of developing new antibiotics, here we ask the question, "Can we recycle the old antibiotics"? With traditional antibiotics like penicillin G, amoxicillin, ampicillin, and so on, can we give them new life"? In the United States every year, around 100,000 patients die of bacteria-induced infections," said senior author Dr. Chuanbing Tang, professor of chemistry and biochemistry at the University of South Carolina. "And the problem is increasing because bacteria are building resistance. It is a really, really big problem, not only for individual patients, but also for society."

Related Links:

University of South Carolina



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.